BioSpace News Archive

Deals

Cargo Therapeutics Plans $315M IPO, Targets Cell Therapies for Cancer

The cell therapy-focused biotech will use most of the net proceeds from its initial public offering to fund Phase II clinical trials for its lead program, a novel CAR T-cell candidate.

November 7, 2023
·
2 min read
·
Tyler Patchen
Merz Therapeutics donates $100,000 to support construction of new rehabilitation center at University of North Carolina

Merz Therapeutics announced today its U.S. organization has made a $100,000 donation to the University of North Carolina (UNC) Health Foundation

November 7, 2023
·
2 min read
Opinion: Cell Therapy Cancer Treatments Are Coming. Now to Make Them More Accessible.

Cell and gene therapy represents the most promising breakthrough in cancer treatment for decades, but it comes with a hefty price tag. Here’s how to drive costs down.

November 7, 2023
·
6 min read
·
Brandon H. McNaughton
Career Advice

In Hiring, Some Companies Move Toward Focus on Skills Over Experience

Newer hiring models based on skills applicants have learned and their general potential for growth could avoid the drawbacks of relying on degrees and experience.

November 7, 2023
·
5 min read
·
Sruthi S. Balakrishnan
Business

Novartis Inks Potential $1.3B Contract with Korean Biotech for Small Molecule

For $80 million upfront and the promise of more than $1.2 billion in milestones, Novartis has bought the global rights to develop an oral HDAC6 inhibitor from Chong Kun Dang Pharmaceutical.

November 7, 2023
·
2 min read
·
Tristan Manalac
Merz Therapeutics to present key data on XEOMIN® (incobotulinumtoxinA) at Toxins 2021 Virtual Conference

18 accepted abstract presentations provide important updates and data on XEOMIN. Abstracts also published in Toxicon, a peer-reviewed interdisciplinary journal on toxins

November 7, 2023
·
11 min read
Drug Development

Ventyx Nixes Psoriasis Candidate Despite Positive Results, Stock Nosedives 75%

Although it hit primary and secondary endpoints in a Phase II study, Ventyx Biosciences concluded that the results weren’t strong enough to face the stiff competition for the indication.

November 7, 2023
·
2 min read
·
Kate Goodwin
Policy

HHS Considers Removing J&J’s Stelara from Medicare Drug Price Negotiations

The Department of Health and Human Services in a court filing last week said that the blockbuster treatment could be “deselected” from the drug price negotiation list, given the recent approval of Amgen’s Stelara biosimilar.

November 7, 2023
·
2 min read
·
Tristan Manalac
Business

Vertex Q3 Revenue Falls Short, Looks to Potential CRISPR Therapy Approval

In the third quarter, Vertex Pharmaceuticals reported revenue of $2.48 billion, a 6% increase from the same period in 2022. However, these figures fell short of Wall Street’s consensus estimates.

November 7, 2023
·
2 min read
·
Tristan Manalac
Job Trends

BioSpace Announces 2024 Best Places to Work in Biopharma

BioSpace has published its annual 2024 Best Places to Work list.

November 7, 2023
·
1 min read
·
Chantal Dresner